靶向嗜酸性肉芽肿性多血管炎的抗体药物研究进展  

Research progress in antibody drugs targeting eosinophilic granulomatosis with polyangiitis

作　　者：崔雪萍 彭红艳 刘灵敏 李娟 邹应梅 CUI Xue-ping;PENG Hong-yan;LIU Ling-min;LI Juan;ZOU Ying-mei(Department of Respiratory and Critical Care Medicine,The First People’s Hospital of Qujing,Qujing Yunnan 655000;Department of Clinical Pharmacy,The First People’s Hospital of Qujing,Qujing Yunnan 655000;Department of Adiministration,Medical the First People’s Hospital of Qujing,Qujing Yunnan 655000)

机构地区：[1]曲靖市第一人民医院呼吸与危重症医学科,云南曲靖655000 [2]曲靖市第一人民医院临床药学科,云南曲靖655000 [3]曲靖市第一人民医院医务部,云南曲靖655000

出　　处：《中南药学》2023年第12期3262-3267,共6页Central South Pharmacy

基　　金：曲靖市第一人民医院院级科研课题(No.2023YJKTF22)。

摘　　要：嗜酸性肉芽肿性多血管炎(EGPA),是可累及全身多个系统、罕见的一种自身免疫性疾病,主要表现为外周血及组织中嗜酸性粒细胞(EOS)增多、浸润及中小血管的坏死性肉芽肿炎症。EGPA治疗的主要药物为糖皮质激素和免疫抑制剂,但长期使用这些药物可出现骨质疏松、感染、血糖控制不佳等并发症。当前,靶向EGPA的抗体药物已面世,并逐渐被临床医师用于治疗EGPA。本文旨在综述靶向EGPA的抗体药物研究进展。Eosinophilic granulomatosis with polyangiitis(EGPA)is a rare autoimmune disease that involves multiple systems throughout the body,mainly presenting by increased eosinophils(EOS)in the peripheral blood and tissues,infiltration and necrotizing granulomous inflammation of small and medium blood vessels.The main drugs for EGPA treatment are glucocorticoids(GC)and immunosuppressants,but long-term use can cause complications such as osteoporosis,infection and poor blood glucose control.Previously,antibody drugs targeting EGPA have been available and are gradually used for EGPA.This paper reviewed the progress of antibody drugs targeting EGPA.

关 键 词：靶向 抗IGE抗体 抗IL-5/IL-5R抗体 抗CD20抗体 嗜酸性肉芽肿性多血管炎 

分 类 号：R963[医药卫生—微生物与生化药学]